{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:25:56Z","timestamp":1795202756632,"version":"4.10.3"},"reference-count":276,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA036727"],"award-info":[{"award-number":["P30 CA036727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA258621"],"award-info":[{"award-number":["R01 CA258621"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The unfolded protein response pathway is an evolutionarily conserved cytoprotective signaling cascade, essential for cell function and survival. Unfolded protein response signaling is tightly integrated with bone cell differentiation and function, and chronic unfolded protein response activation has been identified in bone disease. The unfolded protein response has been found to promote oncogenesis and drug resistance, raising the possibility that unfolded protein response modulators may have activity as anti-cancer agents. Cancer-associated bone disease remains a major cause of morbidity for patients with multiple myeloma or bone-metastatic disease. Understanding the critical role of unfolded protein response signaling in cancer development and metastasis, as well as its role in bone homeostasis, may lead to novel mechanisms by which to target cancer-associated bone disease. In this review, we summarize the current research delineating the roles of the unfolded protein response in bone biology and pathophysiology, and furthermore, review unfolded protein response modulating agents in the contexts of cancer and cancer-associated bone disease.<\/jats:p>","DOI":"10.1038\/s41413-025-00457-6","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:35:16Z","timestamp":1756366516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of the unfolded protein response pathway in bone homeostasis and potential therapeutic target in cancer-associated bone disease"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7448-0775","authenticated-orcid":false,"given":"Molly E.","family":"Muehlebach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-5635","authenticated-orcid":false,"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1152\/physrev.00050.2006","volume":"87","author":"DN Hebert","year":"2007","unstructured":"Hebert, D. N. & Molinari, M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 87, 1377\u20131408 (2007).","journal-title":"Physiol. Rev."},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","volume":"21","author":"C Hetz","year":"2020","unstructured":"Hetz, C., Zhang, K. & Kaufman, R. J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421\u2013438 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"457_CR3","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.molcel.2022.03.025","volume":"82","author":"RL Wiseman","year":"2022","unstructured":"Wiseman, R. L., Mesgarzadeh, J. S. & Hendershot, L. M. Reshaping endoplasmic reticulum quality control through the unfolded protein response. Mol. Cell. 82, 1477\u20131491 (2022).","journal-title":"Mol. Cell."},{"key":"457_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89\u2013102 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/sj.cdd.4401840","volume":"13","author":"J Wu","year":"2006","unstructured":"Wu, J. & Kaufman, R. J. From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ. 13, 374\u2013384 (2006).","journal-title":"Cell Death Differ."},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen, X. & Cubillos-Ruiz, J. R. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat. Rev. Cancer 21, 71\u201388 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"457_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4049\/immunohorizons.2200064","volume":"7","author":"LN Raines","year":"2023","unstructured":"Raines, L. N. & Huang, S. C. How the unfolded protein response is a boon for tumors and a bane for the immune system. Immunohorizons 7, 256\u2013264 (2023).","journal-title":"Immunohorizons"},{"key":"457_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fonc.2020.01100","volume":"10","author":"L Xu","year":"2020","unstructured":"Xu, L., Zhang, W., Zhang, X. H. & Chen, X. Endoplasmic reticulum stress in bone metastases. Front Oncol. 10, 1100 (2020).","journal-title":"Front Oncol."},{"key":"457_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.750","volume":"12","author":"C Shi","year":"2022","unstructured":"Shi, C. et al. A novel prognostic signature in osteosarcoma characterised from the perspective of unfolded protein response. Clin. Transl. Med. 12, e750 (2022).","journal-title":"Clin. Transl. Med."},{"key":"457_CR10","doi-asserted-by":"crossref","unstructured":"Jiang, D. et al. Comprehensive analysis of the unfolded protein response in breast cancer subtypes. JCO Precis Oncol 1, 1-9 (2017).","DOI":"10.1200\/PO.16.00073"},{"key":"457_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neo.2019.02.004","volume":"21","author":"S Yarapureddy","year":"2019","unstructured":"Yarapureddy, S. et al. ATF6\u03b1 activation enhances survival against chemotherapy and serves as a prognostic indicator in osteosarcoma. Neoplasia 21, 516\u2013532 (2019).","journal-title":"Neoplasia"},{"key":"457_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2010-01-263236","volume":"116","author":"T Bagratuni","year":"2010","unstructured":"Bagratuni, T. et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 116, 250\u2013253 (2010).","journal-title":"Blood"},{"key":"457_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/pmic.200500306","volume":"6","author":"JM Luk","year":"2006","unstructured":"Luk, J. M. et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 6, 1049\u20131057 (2006).","journal-title":"Proteomics"},{"key":"457_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/path.2795","volume":"223","author":"SS Tan","year":"2011","unstructured":"Tan, S. S. et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J. Pathol. 223, 81\u201387 (2011).","journal-title":"J. Pathol."},{"key":"457_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000330883","volume":"87","author":"K Kuroda","year":"2011","unstructured":"Kuroda, K. et al. Glucose-regulated protein 78 positivity as a predictor of poor survival in patients with renal cell carcinoma. Urol. Int. 87, 450\u2013456 (2011).","journal-title":"Urol. Int."},{"key":"457_CR16","doi-asserted-by":"publisher","first-page":"115783","DOI":"10.1016\/j.bone.2020.115783","volume":"158","author":"C Ryan","year":"2022","unstructured":"Ryan, C. et al. Epidemiology of bone metastases. Bone 158, 115783 (2022).","journal-title":"Bone"},{"key":"457_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fonc.2019.00082","volume":"9","author":"V Ingangi","year":"2019","unstructured":"Ingangi, V. et al. Role of microenvironment on the fate of disseminating cancer stem cells. Front. Oncol. 9, 82 (2019).","journal-title":"Front. Oncol."},{"key":"457_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2020.03.55","volume":"8","author":"JF Huang","year":"2020","unstructured":"Huang, J. F. et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann. Transl. Med. 8, 482 (2020).","journal-title":"Ann. Transl. Med."},{"key":"457_CR19","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","volume":"24","author":"R Rizzoli","year":"2013","unstructured":"Rizzoli, R. et al. Cancer-associated bone disease. Osteoporos. Int. 24, 2929\u20132953 (2013).","journal-title":"Osteoporos. Int."},{"key":"457_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","volume":"76","author":"R von Moos","year":"2019","unstructured":"von Moos, R. et al. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat. Rev. 76, 57\u201367 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"457_CR21","first-page":"004","volume":"15","author":"S D\u2019Oronzo","year":"2019","unstructured":"D\u2019Oronzo, S., Coleman, R., Brown, J. & Silvestris, F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J. Bone Oncol. 15, 004\u2013004 (2019).","journal-title":"J. Bone Oncol."},{"key":"457_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","volume":"62","author":"AF de Groot","year":"2018","unstructured":"de Groot, A. F., Appelman-Dijkstra, N. M., van der Burg, S. H. & Kroep, J. R. The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2014a systematic review. Cancer Treat. Rev. 62, 18\u201328 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"457_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","volume":"3","author":"J Zekri","year":"2014","unstructured":"Zekri, J., Mansour, M. & Karim, S. M. The anti-tumour effects of zoledronic acid. J. Bone Oncol. 3, 25\u201335 (2014).","journal-title":"J. Bone Oncol."},{"key":"457_CR24","doi-asserted-by":"crossref","unstructured":"Read, A. & Schroder, M. The unfolded protein response: an overview. Biology 10, 348 (2021).","DOI":"10.3390\/biology10050384"},{"key":"457_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/16729","volume":"397","author":"HP Harding","year":"1999","unstructured":"Harding, H. P., Zhang, Y. & Ron, D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271\u2013274 (1999).","journal-title":"Nature"},{"key":"457_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","volume":"11","author":"HP Harding","year":"2003","unstructured":"Harding, H. P. et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell. 11, 619\u2013633 (2003).","journal-title":"Mol. Cell."},{"key":"457_CR27","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1128\/MCB.23.4.1292-1303.2003","volume":"23","author":"MH Brush","year":"2003","unstructured":"Brush, M. H., Weiser, D. C. & Shenolikar, S. Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. Mol. Cell Biol. 23, 1292\u20131303 (2003).","journal-title":"Mol. Cell Biol."},{"key":"457_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","volume":"107","author":"H Yoshida","year":"2001","unstructured":"Yoshida, H. et al. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881\u2013891 (2001).","journal-title":"Cell"},{"key":"457_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.devcel.2007.07.005","volume":"13","author":"J Wu","year":"2007","unstructured":"Wu, J. et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell. 13, 351\u2013364 (2007).","journal-title":"Dev. Cell."},{"key":"457_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1101\/gad.12.7.982","volume":"12","author":"H Zinszner","year":"1998","unstructured":"Zinszner, H. et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982\u2013995 (1998).","journal-title":"Genes Dev."},{"key":"457_CR31","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1128\/MCB.21.4.1249-1259.2001","volume":"21","author":"KD McCullough","year":"2001","unstructured":"McCullough, K. D. et al. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell Biol. 21, 1249\u20131259 (2001).","journal-title":"Mol. Cell Biol."},{"key":"457_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.1129631","volume":"313","author":"J Hollien","year":"2006","unstructured":"Hollien, J. & Weissman, J. S. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 313, 104\u2013107 (2006).","journal-title":"Science"},{"key":"457_CR33","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.287.5453.664","volume":"287","author":"F Urano","year":"2000","unstructured":"Urano, F. et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664\u2013666 (2000).","journal-title":"Science"},{"key":"457_CR34","doi-asserted-by":"publisher","first-page":"13935","DOI":"10.1074\/jbc.M010677200","volume":"276","author":"T Yoneda","year":"2001","unstructured":"Yoneda, T. et al. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J. Biol. Chem. 276, 13935\u201313940 (2001).","journal-title":"J. Biol. Chem."},{"key":"457_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1017\/erm.2021.2","volume":"23","author":"M Khanna","year":"2021","unstructured":"Khanna, M., Agrawal, N., Chandra, R. & Dhawan, G. Targeting unfolded protein response: a new horizon for disease control. Expert Rev. Mol. Med. 23, e1 (2021).","journal-title":"Expert Rev. Mol. Med."},{"key":"457_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2015.03.003","volume":"33","author":"M Maurel","year":"2015","unstructured":"Maurel, M. et al. Controlling the unfolded protein response-mediated life and death decisions in cancer. Semin Cancer Biol. 33, 57\u201366 (2015).","journal-title":"Semin Cancer Biol."},{"key":"457_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14, 581\u2013597 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"457_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrd3976","volume":"12","author":"C Hetz","year":"2013","unstructured":"Hetz, C., Chevet, E. & Harding, H. P. Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 12, 703\u2013719 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"457_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1083\/jcb.201110131","volume":"197","author":"S Wang","year":"2012","unstructured":"Wang, S. & Kaufman, R. J. The impact of the unfolded protein response on human disease. J. Cell Biol. 197, 857\u2013867 (2012).","journal-title":"J. Cell Biol."},{"key":"457_CR40","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00018-016-2178-1","volume":"73","author":"K Horiuchi","year":"2016","unstructured":"Horiuchi, K., Tohmonda, T. & Morioka, H. The unfolded protein response in skeletal development and homeostasis. Cell Mol. Life Sci. 73, 2851\u20132869 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"457_CR41","doi-asserted-by":"crossref","unstructured":"Huang, W., Gong, Y. & Yan, L. ER stress, the unfolded protein response and osteoclastogenesis: a review. Biomolecules. 13, 1050 (2023).","DOI":"10.3390\/biom13071050"},{"key":"457_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00223-023-01096-x","volume":"113","author":"S Iyer","year":"2023","unstructured":"Iyer, S. & Adams, D. J. Bone and the unfolded protein response: in sickness and in health. Calcif. Tissue Int. 113, 96\u2013109 (2023).","journal-title":"Calcif. Tissue Int."},{"key":"457_CR43","doi-asserted-by":"publisher","first-page":"1217579","DOI":"10.3389\/fendo.2023.1217579","volume":"14","author":"W Lv","year":"2023","unstructured":"Lv, W. et al. The Role of XBP1 in bone metabolism. Front Endocrinol. 14, 1217579 (2023).","journal-title":"Front Endocrinol."},{"key":"457_CR44","doi-asserted-by":"crossref","unstructured":"Hughes, A. et al. Endoplasmic reticulum stress and unfolded protein response in cartilage pathophysiology: contributing factors to apoptosis and osteoarthritis. Int. J. Mol. Sci. 18, 665 (2017).","DOI":"10.3390\/ijms18030665"},{"key":"457_CR45","doi-asserted-by":"publisher","first-page":"109880","DOI":"10.1016\/j.cellsig.2020.109880","volume":"78","author":"Y Rellmann","year":"2021","unstructured":"Rellmann, Y., Eidhof, E. & Dreier, R. Review: ER stress-induced cell death in osteoarthritic cartilage. Cell Signal. 78, 109880 (2021).","journal-title":"Cell Signal."},{"key":"457_CR46","first-page":"14","volume":"1","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. Perspective study of upr signaling molecules as potential biomarkers in bone metabolism. Cell Signal. 1, 14\u201321 (2023).","journal-title":"Cell Signal."},{"key":"457_CR47","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2337\/diabetes.51.7.2301","volume":"51","author":"A Biason-Lauber","year":"2002","unstructured":"Biason-Lauber, A., Lang-Muritano, M., Vaccaro, T. & Schoenle, E. J. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. Diabetes 51, 2301\u20132305 (2002).","journal-title":"Diabetes"},{"key":"457_CR48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/78085","volume":"25","author":"M Del\u00e9pine","year":"2000","unstructured":"Del\u00e9pine, M. et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25, 406\u2013409 (2000).","journal-title":"Nat. Genet."},{"key":"457_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/jmg.40.9.685","volume":"40","author":"S Brickwood","year":"2003","unstructured":"Brickwood, S. et al. Wolcott-Rallison syndrome: pathogenic insights into neonatal diabetes from new mutation and expression studies of EIF2AK3. J. Med. Genet. 40, 685\u2013689 (2003).","journal-title":"J. Med. Genet."},{"key":"457_CR50","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0022-3476(66)80320-7","volume":"69","author":"R Coffin","year":"1966","unstructured":"Coffin, R., Phillips, J. L., Staples, W. I. & Spector, S. Treatment of lead encephalopathy in children. J. Pediatr. 69, 198\u2013206 (1966).","journal-title":"J. Pediatr."},{"key":"457_CR51","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1001\/archpedi.1971.02100170078009","volume":"121","author":"B Lowry","year":"1971","unstructured":"Lowry, B., Miller, J. R. & Fraser, F. C. A new dominant gene mental retardation syndrome. Association with small stature, tapering fingers, characteristic facies, and possible hydrocephalus. Am. J. Dis. Child. 121, 496\u2013500 (1971).","journal-title":"Am. J. Dis. Child."},{"key":"457_CR52","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0092-8674(04)00344-7","volume":"117","author":"X Yang","year":"2004","unstructured":"Yang, X. et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117, 387\u2013398 (2004).","journal-title":"Cell"},{"key":"457_CR53","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1091\/mbc.10.11.3787","volume":"10","author":"K Haze","year":"1999","unstructured":"Haze, K. et al. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol. Biol. Cell. 10, 3787\u20133799 (1999).","journal-title":"Mol. Biol. Cell."},{"key":"457_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11920","volume":"7","author":"U Lindert","year":"2016","unstructured":"Lindert, U. et al. MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. Nat. Commun. 7, 11920 (2016).","journal-title":"Nat. Commun."},{"key":"457_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17347-0","volume":"12","author":"A Duxfield","year":"2022","unstructured":"Duxfield, A., Munkley, J., Briggs, M. D. & Dennis, E. P. CRELD2 is a novel modulator of calcium release and calcineurin-NFAT signalling during osteoclast differentiation. Sci. Rep. 12, 13884 (2022).","journal-title":"Sci. Rep."},{"key":"457_CR56","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1093\/hmg\/ddt383","volume":"22","author":"CL Hartley","year":"2013","unstructured":"Hartley, C. L. et al. Armet\/Manf and Creld2 are components of a specialized ER stress response provoked by inappropriate formation of disulphide bonds: implications for genetic skeletal diseases. Hum. Mol. Genet. 22, 5262\u20135275 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"457_CR57","doi-asserted-by":"crossref","unstructured":"Yahara, Y. et al. The origins and roles of osteoclasts in bone development, homeostasis and repair. Development. 149, dev199908 (2022).","DOI":"10.1242\/dev.199908"},{"key":"457_CR58","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/mpo.10334","volume":"41","author":"RL Jilka","year":"2003","unstructured":"Jilka, R. L. Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med. Pediatr. Oncol. 41, 182\u2013185 (2003).","journal-title":"Med. Pediatr. Oncol."},{"key":"457_CR59","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231\u20131234 (2011).","journal-title":"Nat. Med."},{"key":"457_CR60","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/nm.2448","volume":"17","author":"J Xiong","year":"2011","unstructured":"Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235\u20131241 (2011).","journal-title":"Nat. Med."},{"key":"457_CR61","doi-asserted-by":"crossref","unstructured":"Takito, J. & Nakamura, M. Heterogeneity and actin cytoskeleton in osteoclast and macrophage multinucleation. Int. J. Mol. Sci. 21, 6629 (2020).","DOI":"10.3390\/ijms21186629"},{"key":"457_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1749-6632.2011.06283.x","volume":"1240","author":"SL Teitelbaum","year":"2011","unstructured":"Teitelbaum, S. L. The osteoclast and its unique cytoskeleton. Ann. N. Y. Acad. Sci. 1240, 14\u201317 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"457_CR63","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1042\/BST20180445","volume":"47","author":"PY Ng","year":"2019","unstructured":"Ng, P. Y., Brigitte Patricia Ribet, A. & Pavlos, N. J. Membrane trafficking in osteoclasts and implications for osteoporosis. Biochem Soc. Trans. 47, 639\u2013650 (2019).","journal-title":"Biochem Soc. Trans."},{"key":"457_CR64","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1021\/acscentsci.9b00220","volume":"5","author":"M Minoshima","year":"2019","unstructured":"Minoshima, M. et al. In vivo multicolor imaging with fluorescent probes revealed the dynamics and function of osteoclast proton pumps. ACS Cent. Sci. 5, 1059\u20131066 (2019).","journal-title":"ACS Cent. Sci."},{"key":"457_CR65","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.2741\/2296","volume":"12","author":"W Huang","year":"2007","unstructured":"Huang, W., Yang, S., Shao, J. & Li, Y. P. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front. Biosci. 12, 3068\u20133092 (2007).","journal-title":"Front. Biosci."},{"key":"457_CR66","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1101\/gad.1276205","volume":"19","author":"M Murshed","year":"2005","unstructured":"Murshed, M. et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 19, 1093\u20131104 (2005).","journal-title":"Genes Dev."},{"key":"457_CR67","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/cdd.2015.14","volume":"22","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Osteoblast-induced osteoclast apoptosis by Fas ligand\/FAS pathway is required for maintenance of bone mass. Cell Death Differ. 22, 1654\u20131664 (2015).","journal-title":"Cell Death Differ."},{"key":"457_CR68","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/dvdy.20603","volume":"235","author":"TA Franz-Odendaal","year":"2006","unstructured":"Franz-Odendaal, T. A., Hall, B. K. & Witten, P. E. Buried alive: how osteoblasts become osteocytes. Dev. Dyn. 235, 176\u2013190 (2006).","journal-title":"Dev. Dyn."},{"key":"457_CR69","doi-asserted-by":"publisher","first-page":"706","DOI":"10.14348\/molcells.2017.0225","volume":"40","author":"JH Park","year":"2017","unstructured":"Park, J. H., Lee, N. K. & Lee, S. Y. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol. Cells 40, 706\u2013713 (2017).","journal-title":"Mol. Cells"},{"key":"457_CR70","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","volume":"40","author":"M Asagiri","year":"2007","unstructured":"Asagiri, M. & Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 40, 251\u2013264 (2007).","journal-title":"Bone"},{"key":"457_CR71","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00109-004-0612-6","volume":"83","author":"H Takayanagi","year":"2005","unstructured":"Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170\u2013179 (2005).","journal-title":"J. Mol. Med."},{"key":"457_CR72","doi-asserted-by":"crossref","unstructured":"Ponzetti, M. & Rucci, N. Osteoblast differentiation and signaling: established concepts and emerging topics. Int. J. Mol. Sci. 22, 6651 (2021).","DOI":"10.3390\/ijms22136651"},{"key":"457_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41421-024-00689-6","volume":"10","author":"S Zhu","year":"2024","unstructured":"Zhu, S., Chen, W., Masson, A. & Li, Y. P. Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis. Cell Discov. 10, 71 (2024).","journal-title":"Cell Discov."},{"key":"457_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12079-021-00635-1","volume":"16","author":"S Thomas","year":"2022","unstructured":"Thomas, S. & Jaganathan, B. G. Signaling network regulating osteogenesis in mesenchymal stem cells. J. Cell Commun. Signal. 16, 47\u201361 (2022).","journal-title":"J. Cell Commun. Signal."},{"key":"457_CR75","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-pathmechdis-031521-040919","volume":"18","author":"DJ Veis","year":"2023","unstructured":"Veis, D. J. & O\u2019Brien, C. A. Osteoclasts, master sculptors of bone. Annu. Rev. Pathol. 18, 257\u2013281 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"457_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41556-019-0437-8","volume":"22","author":"Y Yahara","year":"2020","unstructured":"Yahara, Y. et al. Erythromyeloid progenitors give rise to a population of osteoclasts that contribute to bone homeostasis and repair. Nat. Cell Biol. 22, 49\u201359 (2020).","journal-title":"Nat. Cell Biol."},{"key":"457_CR77","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41586-019-1105-7","volume":"568","author":"CE Jacome-Galarza","year":"2019","unstructured":"Jacome-Galarza, C. E. et al. Developmental origin, functional maintenance and genetic rescue of osteoclasts. Nature 568, 541\u2013545 (2019).","journal-title":"Nature"},{"key":"457_CR78","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","volume":"52","author":"SH Mun","year":"2020","unstructured":"Mun, S. H., Park, P. S. U. & Park-Min, K. H. The M-CSF receptor in osteoclasts and beyond. Exp. Mol. Med. 52, 1239\u20131254 (2020).","journal-title":"Exp. Mol. Med."},{"key":"457_CR79","doi-asserted-by":"publisher","first-page":"E714","DOI":"10.1152\/ajpendo.90631.2008","volume":"296","author":"GQ Yao","year":"2009","unstructured":"Yao, G. Q. et al. Targeted overexpression of the two colony-stimulating factor-1 isoforms in osteoblasts differentially affects bone loss in ovariectomized mice. Am. J. Physiol. Endocrinol. Metab. 296, E714\u2013E720 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"457_CR80","doi-asserted-by":"publisher","first-page":"778078","DOI":"10.3389\/fimmu.2021.778078","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Macrophage-osteoclast associations: origin, polarization, and subgroups. Front Immunol. 12, 778078 (2021).","journal-title":"Front Immunol."},{"key":"457_CR81","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s42255-020-00318-y","volume":"2","author":"M Tsukasaki","year":"2020","unstructured":"Tsukasaki, M. et al. Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution. Nat. Metab. 2, 1382\u20131390 (2020).","journal-title":"Nat. Metab."},{"key":"457_CR82","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/emboj\/20.6.1271","volume":"20","author":"N Kobayashi","year":"2001","unstructured":"Kobayashi, N. et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20, 1271\u20131280 (2001).","journal-title":"EMBO J."},{"key":"457_CR83","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1101\/gad.13.8.1015","volume":"13","author":"MA Lomaga","year":"1999","unstructured":"Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015\u20131024 (1999).","journal-title":"Genes Dev."},{"key":"457_CR84","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1084\/jem.20051150","volume":"202","author":"M Asagiri","year":"2005","unstructured":"Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261\u20131269 (2005).","journal-title":"J. Exp. Med."},{"key":"457_CR85","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1359\/JBMR.041213","volume":"20","author":"H Takatsuna","year":"2005","unstructured":"Takatsuna, H. et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J. Bone Min. Res. 20, 653\u2013662 (2005).","journal-title":"J. Bone Min. Res."},{"key":"457_CR86","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1073\/pnas.1211383110","volume":"110","author":"W Chen","year":"2013","unstructured":"Chen, W. et al. C\/EBPalpha regulates osteoclast lineage commitment. Proc. Natl. Acad. Sci. USA 110, 7294\u20137299 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"457_CR87","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1126\/science.7939685","volume":"266","author":"AE Grigoriadis","year":"1994","unstructured":"Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443\u2013448 (1994).","journal-title":"Science"},{"key":"457_CR88","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature02444","volume":"428","author":"T Koga","year":"2004","unstructured":"Koga, T. et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428, 758\u2013763 (2004).","journal-title":"Nature"},{"key":"457_CR89","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","volume":"132","author":"M Shinohara","year":"2008","unstructured":"Shinohara, M. et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132, 794\u2013806 (2008).","journal-title":"Cell"},{"key":"457_CR90","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1101\/gad.1102703","volume":"17","author":"PG Hogan","year":"2003","unstructured":"Hogan, P. G., Chen, L., Nardone, J. & Rao, A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17, 2205\u20132232 (2003).","journal-title":"Genes Dev."},{"key":"457_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yexcr.2004.07.035","volume":"301","author":"H Ha","year":"2004","unstructured":"Ha, H. et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res. 301, 119\u2013127 (2004).","journal-title":"Exp. Cell Res."},{"key":"457_CR92","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood-2004-09-3662","volume":"106","author":"NK Lee","year":"2005","unstructured":"Lee, N. K. et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106, 852\u2013859 (2005).","journal-title":"Blood"},{"key":"457_CR93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11010-006-0333-y","volume":"281","author":"NK Lee","year":"2006","unstructured":"Lee, N. K., Choi, H. K., Kim, D. K. & Lee, S. Y. Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-kappa B activation. Mol. Cell. Biochem. 281, 55\u201361 (2006).","journal-title":"Mol. Cell. Biochem."},{"key":"457_CR94","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.7150\/thno.35414","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics 9, 4648\u20134662 (2019).","journal-title":"Theranostics"},{"key":"457_CR95","doi-asserted-by":"publisher","first-page":"45969","DOI":"10.1074\/jbc.M408795200","volume":"279","author":"M Matsumoto","year":"2004","unstructured":"Matsumoto, M. et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. Chem. 279, 45969\u201345979 (2004).","journal-title":"J. Biol. Chem."},{"key":"457_CR96","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3, 889\u2013901 (2002).","journal-title":"Dev. Cell."},{"key":"457_CR97","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1083\/jcb.111.3.1305","volume":"111","author":"HK V\u00e4\u00e4n\u00e4nen","year":"1990","unstructured":"V\u00e4\u00e4n\u00e4nen, H. K. et al. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J. Cell Biol. 111, 1305\u20131311 (1990).","journal-title":"J. Cell Biol."},{"key":"457_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1210\/me.2007-0237","volume":"22","author":"K Kim","year":"2008","unstructured":"Kim, K. et al. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 22, 176\u2013185 (2008).","journal-title":"Mol. Endocrinol."},{"key":"457_CR99","doi-asserted-by":"publisher","first-page":"35209","DOI":"10.1074\/jbc.M505815200","volume":"280","author":"K Kim","year":"2005","unstructured":"Kim, K. et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 280, 35209\u201335216 (2005).","journal-title":"J. Biol. Chem."},{"key":"457_CR100","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1083\/jcb.201111116","volume":"197","author":"T Oikawa","year":"2012","unstructured":"Oikawa, T. et al. Tks5-dependent formation of circumferential podosomes\/invadopodia mediates cell-cell fusion. J. Cell Biol. 197, 553\u2013568 (2012).","journal-title":"J. Cell Biol."},{"key":"457_CR101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gene.2005.12.012","volume":"372","author":"TN Crotti","year":"2006","unstructured":"Crotti, T. N. et al. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene 372, 92\u2013102 (2006).","journal-title":"Gene"},{"key":"457_CR102","doi-asserted-by":"publisher","first-page":"24209","DOI":"10.1074\/jbc.M302940200","volume":"278","author":"H So","year":"2003","unstructured":"So, H. et al. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J. Biol. Chem. 278, 24209\u201324216 (2003).","journal-title":"J. Biol. Chem."},{"key":"457_CR103","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1242\/jcs.112.22.3985","volume":"112","author":"I Nakamura","year":"1999","unstructured":"Nakamura, I. et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J. Cell Sci. 112, 3985\u20133993 (1999).","journal-title":"J. Cell Sci."},{"key":"457_CR104","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nm1194","volume":"11","author":"R Faccio","year":"2005","unstructured":"Faccio, R. et al. Vav3 regulates osteoclast function and bone mass. Nat. Med. 11, 284\u2013290 (2005).","journal-title":"Nat. Med."},{"key":"457_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2011.06249.x","volume":"1240","author":"TJ Chambers","year":"2011","unstructured":"Chambers, T. J. & Fuller, K. How are osteoclasts induced to resorb bone? Ann. N. Y. Acad. Sci. 1240, 1\u20136 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"457_CR106","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1083\/jcb.200611083","volume":"176","author":"W Zou","year":"2007","unstructured":"Zou, W. et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell Biol. 176, 877\u2013888 (2007).","journal-title":"J. Cell Biol."},{"key":"457_CR107","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143\u2013147 (1999).","journal-title":"Science"},{"key":"457_CR108","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41574-024-01039-y","volume":"21","author":"S Melis","year":"2025","unstructured":"Melis, S., Trompet, D., Chagin, A. S. & Maes, C. Skeletal stem and progenitor cells in bone physiology, ageing and disease. Nat. Rev. Endocrinol. 21, 135\u2013153 (2025).","journal-title":"Nat. Rev. Endocrinol."},{"key":"457_CR109","doi-asserted-by":"publisher","first-page":"8783","DOI":"10.1128\/MCB.20.23.8783-8792.2000","volume":"20","author":"KS Lee","year":"2000","unstructured":"Lee, K. S. et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol. Cell Biol. 20, 8783\u20138792 (2000).","journal-title":"Mol. Cell Biol."},{"key":"457_CR110","doi-asserted-by":"publisher","first-page":"14665","DOI":"10.1073\/pnas.0504750102","volume":"102","author":"H Akiyama","year":"2005","unstructured":"Akiyama, H. et al. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc. Natl. Acad. Sci. USA 102, 14665\u201314670 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"457_CR111","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0092-8674(00)80257-3","volume":"89","author":"P Ducy","year":"1997","unstructured":"Ducy, P. et al. Osf2\/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747\u2013754 (1997).","journal-title":"Cell"},{"key":"457_CR112","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","volume":"108","author":"K Nakashima","year":"2002","unstructured":"Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17\u201329 (2002).","journal-title":"Cell"},{"key":"457_CR113","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1242\/dev.041624","volume":"136","author":"KS Joeng","year":"2009","unstructured":"Joeng, K. S. & Long, F. The Gli2 transcriptional activator is a crucial effector for Ihh signaling in osteoblast development and cartilage vascularization. Development 136, 4177\u20134185 (2009).","journal-title":"Development"},{"key":"457_CR114","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ydbio.2011.11.013","volume":"362","author":"X Tu","year":"2012","unstructured":"Tu, X., Joeng, K. S. & Long, F. Indian hedgehog requires additional effectors besides Runx2 to induce osteoblast differentiation. Dev. Biol. 362, 76\u201382 (2012).","journal-title":"Dev. Biol."},{"key":"457_CR115","doi-asserted-by":"publisher","first-page":"24618","DOI":"10.1074\/jbc.M413834200","volume":"280","author":"I Kalajzic","year":"2005","unstructured":"Kalajzic, I. et al. Expression profile of osteoblast lineage at defined stages of differentiation. J. Biol. Chem. 280, 24618\u201324626 (2005).","journal-title":"J. Biol. Chem."},{"key":"457_CR116","doi-asserted-by":"crossref","unstructured":"Hasegawa, T. et al. Matrix vesicle-mediated mineralization and osteocytic regulation of bone mineralization. Int. J. Mol. Sci. 23, 9941 (2022).","DOI":"10.3390\/ijms23179941"},{"key":"457_CR117","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald, L. F. The amazing osteocyte. J. Bone Min. Res. 26, 229\u2013238 (2011).","journal-title":"J. Bone Min. Res."},{"key":"457_CR118","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1359\/jbmr.2002.17.1.77","volume":"17","author":"V Everts","year":"2002","unstructured":"Everts, V. et al. The bone lining cell: its role in cleaning Howship\u2019s lacunae and initiating bone formation. J. Bone Min. Res. 17, 77\u201390 (2002).","journal-title":"J. Bone Min. Res."},{"key":"457_CR119","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1002\/stem.2474","volume":"34","author":"I Matic","year":"2016","unstructured":"Matic, I. et al. Quiescent bone lining cells are a major source of osteoblasts during adulthood. Stem Cells 34, 2930\u20132942 (2016).","journal-title":"Stem Cells"},{"key":"457_CR120","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1101\/gad.266551.115","volume":"29","author":"DM Ornitz","year":"2015","unstructured":"Ornitz, D. M. & Marie, P. J. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 29, 1463\u20131486 (2015).","journal-title":"Genes Dev."},{"key":"457_CR121","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/nm.2793","volume":"18","author":"L Xian","year":"2012","unstructured":"Xian, L. et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095\u20131101 (2012).","journal-title":"Nat. Med."},{"key":"457_CR122","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen, G., Deng, C. & Li, Y. P. TGF-\u03b2 and BMP signaling in osteoblast differentiation and bone formation. Int. J. Biol. Sci. 8, 272\u2013288 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"457_CR123","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bbrc.2003.08.058","volume":"309","author":"MH Lee","year":"2003","unstructured":"Lee, M. H. et al. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem. Biophys. Res. Commun. 309, 689\u2013694 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"457_CR124","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.1038\/sj.onc.1205937","volume":"21","author":"KS Lee","year":"2002","unstructured":"Lee, K. S., Hong, S. H. & Bae, S. C. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 21, 7156\u20137163 (2002).","journal-title":"Oncogene"},{"key":"457_CR125","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1210\/endrev\/bnac032","volume":"44","author":"JP Vilardaga","year":"2023","unstructured":"Vilardaga, J. P. et al. Molecular mechanisms of PTH\/PTHrP Class B GPCR signaling and pharmacological implications. Endocr. Rev. 44, 474\u2013491 (2023).","journal-title":"Endocr. Rev."},{"key":"457_CR126","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"JJ Westendorf","year":"2004","unstructured":"Westendorf, J. J., Kahler, R. A. & Schroeder, T. M. Wnt signaling in osteoblasts and bone diseases. Gene 341, 19\u201339 (2004).","journal-title":"Gene"},{"key":"457_CR127","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1101\/gad.1702708","volume":"22","author":"M Wan","year":"2008","unstructured":"Wan, M. et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 22, 2968\u20132979 (2008).","journal-title":"Genes Dev."},{"key":"457_CR128","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1073\/pnas.0408742102","volume":"102","author":"CN Bennett","year":"2005","unstructured":"Bennett, C. N. et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl Acad. Sci. USA 102, 3324\u20133329 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"457_CR129","doi-asserted-by":"publisher","first-page":"14515","DOI":"10.1074\/jbc.M700030200","volume":"282","author":"S Kang","year":"2007","unstructured":"Kang, S. et al. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT\/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 282, 14515\u201314524 (2007).","journal-title":"J. Biol. Chem."},{"key":"457_CR130","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1359\/jbmr.070810","volume":"22","author":"CN Bennett","year":"2007","unstructured":"Bennett, C. N. et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J. Bone Min. Res. 22, 1924\u20131932 (2007).","journal-title":"J. Bone Min. Res."},{"key":"457_CR131","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1242\/dev.01564","volume":"132","author":"H Hu","year":"2005","unstructured":"Hu, H. et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132, 49\u201360 (2005).","journal-title":"Development"},{"key":"457_CR132","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1074\/jbc.M109.054338","volume":"285","author":"R Bilkovski","year":"2010","unstructured":"Bilkovski, R. et al. Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J. Biol. Chem. 285, 6170\u20136178 (2010).","journal-title":"J. Biol. Chem."},{"key":"457_CR133","doi-asserted-by":"publisher","first-page":"e5388","DOI":"10.1371\/journal.pone.0005388","volume":"4","author":"EJ Arnsdorf","year":"2009","unstructured":"Arnsdorf, E. J., Tummala, P. & Jacobs, C. R. Non-canonical Wnt signaling and N-cadherin related beta-catenin signaling play a role in mechanically induced osteogenic cell fate. PLoS ONE 4, e5388 (2009).","journal-title":"PLoS ONE"},{"key":"457_CR134","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.devcel.2006.11.003","volume":"12","author":"X Tu","year":"2007","unstructured":"Tu, X. et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev. Cell. 12, 113\u2013127 (2007).","journal-title":"Dev. Cell."},{"key":"457_CR135","doi-asserted-by":"crossref","unstructured":"Besio, R. et al. Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate. Dis. Model. Mech. 12, dmm038521 (2019).","DOI":"10.1242\/dmm.038521"},{"key":"457_CR136","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jcp.21543","volume":"217","author":"J Wei","year":"2008","unstructured":"Wei, J. et al. PERK is essential for neonatal skeletal development to regulate osteoblast proliferation and differentiation. J. Cell Physiol. 217, 693\u2013707 (2008).","journal-title":"J. Cell Physiol."},{"key":"457_CR137","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/B978-0-12-385114-7.00004-0","volume":"490","author":"CM Oslowski","year":"2011","unstructured":"Oslowski, C. M. & Urano, F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 490, 71\u201392 (2011).","journal-title":"Methods Enzymol."},{"key":"457_CR138","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1128\/MCB.22.11.3864-3874.2002","volume":"22","author":"P Zhang","year":"2002","unstructured":"Zhang, P. et al. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell Biol. 22, 3864\u20133874 (2002).","journal-title":"Mol. Cell Biol."},{"key":"457_CR139","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1074\/jbc.M110.152900","volume":"286","author":"A Saito","year":"2011","unstructured":"Saito, A. et al. Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J. Biol. Chem. 286, 4809\u20134818 (2011).","journal-title":"J. Biol. Chem."},{"key":"457_CR140","doi-asserted-by":"publisher","first-page":"47109","DOI":"10.1074\/jbc.M410010200","volume":"279","author":"X Yang","year":"2004","unstructured":"Yang, X. & Karsenty, G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J. Biol. Chem. 279, 47109\u201347114 (2004).","journal-title":"J. Biol. Chem."},{"key":"457_CR141","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cellsig.2012.11.015","volume":"25","author":"L He","year":"2013","unstructured":"He, L. et al. Osteoporosis regulation by salubrinal through eIF2alpha mediated differentiation of osteoclast and osteoblast. Cell Signal. 25, 552\u2013560 (2013).","journal-title":"Cell Signal."},{"key":"457_CR142","doi-asserted-by":"publisher","first-page":"E590","DOI":"10.1152\/ajpendo.00371.2018","volume":"316","author":"K Zhang","year":"2019","unstructured":"Zhang, K. et al. The PERK-EIF2alpha-ATF4 signaling branch regulates osteoblast differentiation and proliferation by PTH. Am. J. Physiol. Endocrinol. Metab. 316, E590\u2013E604 (2019).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"457_CR143","doi-asserted-by":"crossref","unstructured":"Pawlak, K., Sieklucka, B. & Pawlak, D. Paracrine kynurenic pathway activation in the bone of young uremic rats can antagonize anabolic effects of PTH on bone turnover and strength through the disruption of PTH-dependent molecular signaling. Int. J. Mol. Sci. 22, 6563 (2021).","DOI":"10.3390\/ijms22126563"},{"key":"457_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2159-z","volume":"10","author":"J Li","year":"2019","unstructured":"Li, J. et al. eIF2\u03b1 signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice. Cell Death Dis. 10, 921 (2019).","journal-title":"Cell Death Dis."},{"key":"457_CR145","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/embor.2011.34","volume":"12","author":"T Tohmonda","year":"2011","unstructured":"Tohmonda, T. et al. The IRE1\u03b1-XBP1 pathway is essential for osteoblast differentiation through promoting transcription of Osterix. EMBO Rep. 12, 451\u2013457 (2011).","journal-title":"EMBO Rep."},{"key":"457_CR146","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1074\/jbc.C112.424606","volume":"288","author":"T Tohmonda","year":"2013","unstructured":"Tohmonda, T. et al. The IRE1alpha-XBP1 pathway positively regulates parathyroid hormone (PTH)\/PTH-related peptide receptor expression and is involved in pth-induced osteoclastogenesis. J. Biol. Chem. 288, 1691\u20131695 (2013).","journal-title":"J. Biol. Chem."},{"key":"457_CR147","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1096\/fba.2019-00032","volume":"2","author":"S Iyer","year":"2020","unstructured":"Iyer, S. et al. Elevation of the unfolded protein response increases RANKL expression. FASEB Bioadvance 2, 207\u2013218 (2020).","journal-title":"FASEB Bioadvance"},{"key":"457_CR148","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1074\/jbc.M111.253187","volume":"287","author":"WG Jang","year":"2012","unstructured":"Jang, W. G. et al. BMP2 protein regulates osteocalcin expression via Runx2-mediated Atf6 gene transcription. J. Biol. Chem. 287, 905\u2013915 (2012).","journal-title":"J. Biol. Chem."},{"key":"457_CR149","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/ncb1963","volume":"11","author":"T Murakami","year":"2009","unstructured":"Murakami, T. et al. Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat. Cell Biol. 11, 1205\u20131211 (2009).","journal-title":"Nat. Cell Biol."},{"key":"457_CR150","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bone.2010.10.176","volume":"48","author":"T Murakami","year":"2011","unstructured":"Murakami, T. et al. Distinct mechanisms are responsible for osteopenia and growth retardation in OASIS-deficient mice. Bone 48, 514\u2013523 (2011).","journal-title":"Bone"},{"key":"457_CR151","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5483\/BMBRep.2011.44.11.735","volume":"44","author":"WG Jang","year":"2011","unstructured":"Jang, W. G., Kim, E. J. & Koh, J. T. Tunicamycin negatively regulates BMP2-induced osteoblast differentiation through CREBH expression in MC3T3E1 cells. BMB Rep. 44, 735\u2013740 (2011).","journal-title":"BMB Rep."},{"key":"457_CR152","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1172\/JCI76765","volume":"125","author":"T Tohmonda","year":"2015","unstructured":"Tohmonda, T. et al. IRE1\u03b1\/XBP1-mediated branch of the unfolded protein response regulates osteoclastogenesis. J. Clin. Investig. 125, 3269\u20133279 (2015).","journal-title":"J. Clin. Investig."},{"key":"457_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03046-z","volume":"11","author":"J Guo","year":"2020","unstructured":"Guo, J. et al. PERK controls bone homeostasis through the regulation of osteoclast differentiation and function. Cell Death Dis. 11, 847 (2020).","journal-title":"Cell Death Dis."},{"key":"457_CR154","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tox.2014.07.006","volume":"325","author":"F Sun","year":"2014","unstructured":"Sun, F. et al. A role for PERK in the mechanism underlying fluoride-induced bone turnover. Toxicology 325, 52\u201366 (2014).","journal-title":"Toxicology"},{"key":"457_CR155","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1172\/JCI42106","volume":"120","author":"H Cao","year":"2010","unstructured":"Cao, H. et al. Activating transcription factor 4 regulates osteoclast differentiation in mice. J. Clin. Investig. 120, 2755\u20132766 (2010).","journal-title":"J. Clin. Investig."},{"key":"457_CR156","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00774-013-0450-0","volume":"31","author":"K Hamamura","year":"2013","unstructured":"Hamamura, K., Tanjung, N. & Yokota, H. Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J. Bone Min. Metab. 31, 618\u2013628 (2013).","journal-title":"J. Bone Min. Metab."},{"key":"457_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-14-197","volume":"14","author":"H Yokota","year":"2013","unstructured":"Yokota, H. et al. Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells. BMC Musculoskelet. Disord. 14, 197 (2013).","journal-title":"BMC Musculoskelet. Disord."},{"key":"457_CR158","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cellsig.2012.11.015","volume":"25","author":"L He","year":"2013","unstructured":"He, L. et al. Osteoporosis regulation by salubrinal through eIF2\u03b1 mediated differentiation of osteoclast and osteoblast. Cell Signal. 25, 552\u2013560 (2013).","journal-title":"Cell Signal."},{"key":"457_CR159","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cellsig.2014.11.020","volume":"27","author":"K Hamamura","year":"2015","unstructured":"Hamamura, K. et al. In vitro and in silico analysis of an inhibitory mechanism of osteoclastogenesis by salubrinal and guanabenz. Cell Signal. 27, 353\u2013362 (2015).","journal-title":"Cell Signal."},{"key":"457_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2159-z","volume":"10","author":"J Li","year":"2019","unstructured":"Li, J. et al. eIF2alpha signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice. Cell Death Dis. 10, 921 (2019).","journal-title":"Cell Death Dis."},{"key":"457_CR161","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00774-012-0359-z","volume":"30","author":"P Zhang","year":"2012","unstructured":"Zhang, P. et al. Salubrinal promotes healing of surgical wounds in rat femurs. J. Bone Min. Metab. 30, 568\u2013579 (2012).","journal-title":"J. Bone Min. Metab."},{"key":"457_CR162","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2016.12.009","volume":"97","author":"J Li","year":"2017","unstructured":"Li, J. et al. Role of endoplasmic reticulum stress in disuse osteoporosis. Bone 97, 2\u201314 (2017).","journal-title":"Bone"},{"key":"457_CR163","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jbspin.2014.04.012","volume":"81","author":"EG Lee","year":"2014","unstructured":"Lee, E. G. et al. Increased RANKL-mediated osteoclastogenesis by interleukin-1\u03b2 and endoplasmic reticulum stress. Jt. Bone Spine 81, 520\u2013526 (2014).","journal-title":"Jt. Bone Spine"},{"key":"457_CR164","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ncb1962","volume":"11","author":"A Saito","year":"2009","unstructured":"Saito, A. et al. Regulation of endoplasmic reticulum stress response by a BBF2H7-mediated Sec23a pathway is essential for chondrogenesis. Nat. Cell Biol. 11, 1197\u20131204 (2009).","journal-title":"Nat. Cell Biol."},{"key":"457_CR165","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s004180100279","volume":"116","author":"T Nikaido","year":"2001","unstructured":"Nikaido, T. et al. Expression of the novel transcription factor OASIS, which belongs to the CREB\/ATF family, in mouse embryo with special reference to bone development. Histochem. Cell Biol. 116, 141\u2013148 (2001).","journal-title":"Histochem. Cell Biol."},{"key":"457_CR166","first-page":"4353","volume":"128","author":"S Kanemoto","year":"2015","unstructured":"Kanemoto, S. et al. Luman is involved in osteoclastogenesis through the regulation of DC-STAMP expression, stability and localization. J. Cell Sci. 128, 4353\u20134365 (2015).","journal-title":"J. Cell Sci."},{"key":"457_CR167","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1074\/jbc.M206421200","volume":"278","author":"SV Komarova","year":"2003","unstructured":"Komarova, S. V. et al. RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts. J. Biol. Chem. 278, 8286\u20138293 (2003).","journal-title":"J. Biol. Chem."},{"key":"457_CR168","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1359\/JBMR.050324","volume":"20","author":"KH Yip","year":"2005","unstructured":"Yip, K. H. et al. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. J. Bone Min. Res. 20, 1462\u20131471 (2005).","journal-title":"J. Bone Min. Res."},{"key":"457_CR169","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/jmcb\/mjr021","volume":"3","author":"K Wang","year":"2011","unstructured":"Wang, K., Niu, J., Kim, H. & Kolattukudy, P. E. Osteoclast precursor differentiation by MCPIP via oxidative stress, endoplasmic reticulum stress, and autophagy. J. Mol. Cell Biol. 3, 360\u2013368 (2011).","journal-title":"J. Mol. Cell Biol."},{"key":"457_CR170","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.4049\/jimmunol.1701036","volume":"200","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Endoplasmic reticulum-bound transcription factor CREBH stimulates RANKL-induced osteoclastogenesis. J. Immunol. 200, 1661\u20131670 (2018).","journal-title":"J. Immunol."},{"key":"457_CR171","doi-asserted-by":"publisher","first-page":"751845","DOI":"10.3389\/fphar.2021.751845","volume":"12","author":"J Sun","year":"2021","unstructured":"Sun, J. et al. Nox4 promotes RANKL-induced autophagy and osteoclastogenesis via activating ROS\/PERK\/eIF-2alpha\/ATF4 pathway. Front Pharmacol. 12, 751845 (2021).","journal-title":"Front Pharmacol."},{"key":"457_CR172","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/cbin.10861","volume":"42","author":"WS Lee","year":"2018","unstructured":"Lee, W. S. et al. Tacrolimus regulates endoplasmic reticulum stress-mediated osteoclastogenesis and inflammation: in vitro and collagen-induced arthritis mouse model. Cell Biol. Int. 42, 393\u2013402 (2018).","journal-title":"Cell Biol. Int."},{"key":"457_CR173","first-page":"65","volume":"2","author":"G Wang","year":"2010","unstructured":"Wang, G., Yang, Z. Q. & Zhang, K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am. J. Transl. Res. 2, 65\u201374 (2010).","journal-title":"Am. J. Transl. Res."},{"key":"457_CR174","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41392-021-00761-7","volume":"6","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer. Signal Transduct. Target. Ther. 6, 357 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"457_CR175","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1158\/1535-7163.MCT-15-0774","volume":"15","author":"JB Gifford","year":"2016","unstructured":"Gifford, J. B. et al. Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 15, 1043\u20131052 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"457_CR176","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.1158\/0008-5472.CAN-06-1660","volume":"66","author":"E Lee","year":"2006","unstructured":"Lee, E. et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 66, 7849\u20137853 (2006).","journal-title":"Cancer Res."},{"key":"457_CR177","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0168-8278(03)00029-1","volume":"38","author":"M Shuda","year":"2003","unstructured":"Shuda, M. et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol. 38, 605\u2013614 (2003).","journal-title":"J. Hepatol."},{"key":"457_CR178","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-006-9051-9","volume":"23","author":"J Zhang","year":"2006","unstructured":"Zhang, J. et al. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin. Exp. Metastasis. 23, 401\u2013410 (2006).","journal-title":"Clin. Exp. Metastasis."},{"key":"457_CR179","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.humpath.2007.03.014","volume":"38","author":"S Daneshmand","year":"2007","unstructured":"Daneshmand, S. et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 38, 1547\u20131552 (2007).","journal-title":"Hum. Pathol."},{"key":"457_CR180","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1128\/MCB.01145-06","volume":"26","author":"JD Blais","year":"2006","unstructured":"Blais, J. D. et al. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol. Cell Biol. 26, 9517\u20139532 (2006).","journal-title":"Mol. Cell Biol."},{"key":"457_CR181","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1158\/0008-5472.CAN-12-0474","volume":"72","author":"Y Wang","year":"2012","unstructured":"Wang, Y. et al. The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK\/ATF4 pathway. Cancer Res. 72, 5396\u20135406 (2012).","journal-title":"Cancer Res."},{"key":"457_CR182","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1172\/JCI62973","volume":"122","author":"LS Hart","year":"2012","unstructured":"Hart, L. S. et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Investig. 122, 4621\u20134634 (2012).","journal-title":"J. Clin. Investig."},{"key":"457_CR183","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.1128\/MCB.23.20.7198-7209.2003","volume":"23","author":"SB Cullinan","year":"2003","unstructured":"Cullinan, S. B. et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol. 23, 7198\u20137209 (2003).","journal-title":"Mol. Cell Biol."},{"key":"457_CR184","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1172\/JCI78031","volume":"125","author":"S Dey","year":"2015","unstructured":"Dey, S. et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Investig. 125, 2592\u20132608 (2015).","journal-title":"J. Clin. Investig."},{"key":"457_CR185","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/0008-5472.CAN-12-3109","volume":"73","author":"C Atkins","year":"2013","unstructured":"Atkins, C. et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 73, 1993\u20132002 (2013).","journal-title":"Cancer Res."},{"key":"457_CR186","doi-asserted-by":"crossref","unstructured":"Axten, J. M. et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 55, 7193\u20137207 (2012). .","DOI":"10.1021\/jm300713s"},{"key":"457_CR187","doi-asserted-by":"publisher","first-page":"15420","DOI":"10.1073\/pnas.1516362112","volume":"112","author":"Q Yu","year":"2015","unstructured":"Yu, Q. et al. Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc. Natl. Acad. Sci. USA 112, 15420\u201315425 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"457_CR188","doi-asserted-by":"publisher","first-page":"e15118","DOI":"10.1200\/JCO.2024.42.16_suppl.e15118","volume":"42","author":"AZ Dudek","year":"2024","unstructured":"Dudek, A. Z. et al. A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors. J. Clin. Oncol. 42, e15118 (2024).","journal-title":"J. Clin. Oncol."},{"key":"457_CR189","doi-asserted-by":"publisher","first-page":"28635","DOI":"10.3390\/ijms161226123","volume":"16","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. Overexpression of X-box binding protein 1 (XBP1) correlates to poor prognosis and up-regulation of PI3K\/mTOR in human osteosarcoma. Int. J. Mol. Sci. 16, 28635\u201328646 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"457_CR190","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3324\/haematol.2013.090142","volume":"99","author":"M Gambella","year":"2014","unstructured":"Gambella, M. et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica 99, e14\u2013e16 (2014).","journal-title":"Haematologica"},{"key":"457_CR191","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13119","volume":"508","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1\u03b1 pathway. Nature 508, 103\u2013107 (2014).","journal-title":"Nature"},{"key":"457_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08152-3","volume":"10","author":"X Sheng","year":"2019","unstructured":"Sheng, X. et al. IRE1\u03b1-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat. Commun. 10, 323 (2019).","journal-title":"Nat. Commun."},{"key":"457_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53039-1","volume":"15","author":"B Unal","year":"2024","unstructured":"Unal, B. et al. Targeting IRE1alpha reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer. Nat. Commun. 15, 8895 (2024).","journal-title":"Nat. Commun."},{"key":"457_CR194","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1158\/0008-5472.CAN-04-1606","volume":"64","author":"L Romero-Ramirez","year":"2004","unstructured":"Romero-Ramirez, L. et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64, 5943\u20135947 (2004).","journal-title":"Cancer Res."},{"key":"457_CR195","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood-2010-08-303099","volume":"117","author":"I Papandreou","year":"2011","unstructured":"Papandreou, I. et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 117, 1311\u20131314 (2011).","journal-title":"Blood"},{"key":"457_CR196","doi-asserted-by":"publisher","first-page":"E869","DOI":"10.1073\/pnas.1115623109","volume":"109","author":"BC Cross","year":"2012","unstructured":"Cross, B. C. et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc. Natl. Acad. Sci. USA 109, E869\u2013E878 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"457_CR197","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","volume":"119","author":"N Mimura","year":"2012","unstructured":"Mimura, N. et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 119, 5772\u20135781 (2012).","journal-title":"Blood"},{"key":"457_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05763-8","volume":"9","author":"SE Logue","year":"2018","unstructured":"Logue, S. E. et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat. Commun. 9, 3267 (2018).","journal-title":"Nat. Commun."},{"key":"457_CR199","first-page":"2156","volume":"5","author":"RM Kumar","year":"2015","unstructured":"Kumar, R. M. et al. Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. Am. J. Cancer Res. 5, 2156\u20132168 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"457_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-32","volume":"13","author":"C Schem","year":"2013","unstructured":"Schem, C. et al. Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases. BMC Cancer 13, 32 (2013).","journal-title":"BMC Cancer"},{"key":"457_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.26","volume":"2","author":"M Ri","year":"2012","unstructured":"Ri, M. et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2, e79 (2012).","journal-title":"Blood Cancer J."},{"key":"457_CR202","first-page":"301","volume":"52","author":"WL Wilson","year":"1968","unstructured":"Wilson, W. L. Phase I study with toyocamycin (NSC-63701). Cancer Chemother. Rep. 52, 301\u2013303 (1968).","journal-title":"Cancer Chemother. Rep."},{"key":"457_CR203","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2013.05.030","volume":"337","author":"D Fessart","year":"2013","unstructured":"Fessart, D. et al. P97\/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 337, 26\u201334 (2013).","journal-title":"Cancer Lett."},{"key":"457_CR204","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.nmd.2009.01.009","volume":"19","author":"CC Weihl","year":"2009","unstructured":"Weihl, C. C., Pestronk, A. & Kimonis, V. E. Valosin-containing protein disease: inclusion body myopathy with Paget\u2019s disease of the bone and fronto-temporal dementia. Neuromuscul. Disord. 19, 308\u2013315 (2009).","journal-title":"Neuromuscul. Disord."},{"key":"457_CR205","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.18632\/aging.204965","volume":"15","author":"R Wei","year":"2023","unstructured":"Wei, R. et al. Inhibition of VCP modulates NF-kappaB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation. Aging (Albany NY). 15, 8220\u20138236 (2023).","journal-title":"Aging (Albany NY)."},{"key":"457_CR206","doi-asserted-by":"crossref","unstructured":"Li, Z. N. & Luo, Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies. Oncol. Rep. 49, 6 (2023).","DOI":"10.3892\/or.2022.8443"},{"key":"457_CR207","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.devcel.2008.02.003","volume":"14","author":"KK Mak","year":"2008","unstructured":"Mak, K. K. et al. Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Dev. Cell. 14, 674\u2013688 (2008).","journal-title":"Dev. Cell."},{"key":"457_CR208","first-page":"1466","volume":"11","author":"Y Wang","year":"2010","unstructured":"Wang, Y., Trepel, J. B., Neckers, L. M. & Giaccone, G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs 11, 1466\u20131476 (2010).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"457_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54944-7","volume":"14","author":"H Al-Daghestani","year":"2024","unstructured":"Al-Daghestani, H. et al. Pharmacological inhibition of endoplasmic reticulum stress mitigates osteoporosis in a mouse model of hindlimb suspension. Sci. Rep. 14, 4719 (2024).","journal-title":"Sci. Rep."},{"key":"457_CR210","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/jbmr.4501","volume":"37","author":"I Duran","year":"2022","unstructured":"Duran, I. et al. 4-PBA treatment improves bone phenotypes in the Aga2 mouse model of osteogenesis imperfecta. J. Bone Min. Res. 37, 675\u2013686 (2022).","journal-title":"J. Bone Min. Res."},{"key":"457_CR211","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1080\/15548627.2018.1483807","volume":"14","author":"H Li","year":"2018","unstructured":"Li, H. et al. Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss. Autophagy 14, 1726\u20131741 (2018).","journal-title":"Autophagy"},{"key":"457_CR212","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers, M. J., M\u00f6nkk\u00f6nen, J. & Munoz, M. A. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139, 115493 (2020).","journal-title":"Bone"},{"key":"457_CR213","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1073\/pnas.96.1.133","volume":"96","author":"JE Fisher","year":"1999","unstructured":"Fisher, J. E. et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96, 133\u2013138 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"457_CR214","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","volume":"264","author":"E van Beek","year":"1999","unstructured":"van Beek, E. et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108\u2013111 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"457_CR215","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon, F. P. et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Min. Res. 15, 1467\u20131476 (2000).","journal-title":"J. Bone Min. Res."},{"key":"457_CR216","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s10238-022-00961-7","volume":"23","author":"A Christou","year":"2023","unstructured":"Christou, A., Ferreira, N. & Sophocleous, A. Effects of zoledronic acid on osteosarcoma progression and metastasis: systematic review and meta-analysis. Clin. Exp. Med. 23, 3041\u20133051 (2023).","journal-title":"Clin. Exp. Med."},{"key":"457_CR217","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989\u20131999 (2010).","journal-title":"Lancet"},{"key":"457_CR218","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jbmr\/zjad006","volume":"39","author":"J Brown","year":"2024","unstructured":"Brown, J. et al. Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study. J. Bone Min. Res. 39, 8\u201316 (2024).","journal-title":"J. Bone Min. Res."},{"key":"457_CR219","doi-asserted-by":"crossref","unstructured":"Zhou, W. et al. Novel therapeutic targets on the horizon: an analysis of clinical trials on therapies for bone metastasis in prostate cancer. Cancers 16, 627 (2024).","DOI":"10.3390\/cancers16030627"},{"key":"457_CR220","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 386, 1353\u20131361 (2015).","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"457_CR221","first-page":"3807","volume":"33","author":"Y-C LAN","year":"2013","unstructured":"LAN, Y.-C. et al. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells. Anticancer Res. 33, 3807\u20133814 (2013).","journal-title":"Anticancer Res."},{"key":"457_CR222","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cmdc.200500059","volume":"1","author":"JM Rondeau","year":"2006","unstructured":"Rondeau, J. M. et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1, 267\u2013273 (2006).","journal-title":"ChemMedChem"},{"key":"457_CR223","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1124\/jpet.119.258624","volume":"371","author":"SL Haney","year":"2019","unstructured":"Haney, S. L. et al. In vivo evaluation of isoprenoid triazole bisphosphonate inhibitors of geranylgeranyl diphosphate synthase: impact of olefin stereochemistry on toxicity and biodistribution. J. Pharmacol. Exp. Ther. 371, 327\u2013338 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"457_CR224","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.leukres.2010.08.008","volume":"35","author":"SA Holstein","year":"2011","unstructured":"Holstein, S. A. & Hohl, R. J. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk. Res. 35, 551\u2013559 (2011).","journal-title":"Leuk. Res."},{"key":"457_CR225","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ddr.22012","volume":"84","author":"SL Haney","year":"2023","unstructured":"Haney, S. L. et al. Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma. Drug Dev. Res. 84, 62\u201374 (2023).","journal-title":"Drug Dev. Res."},{"key":"457_CR226","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00261-6","volume":"11","author":"SL Haney","year":"2022","unstructured":"Haney, S. L. et al. Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma. Exp. Hematol. Oncol. 11, 5 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"457_CR227","volume":"9","author":"ME Muehlebach","year":"2025","unstructured":"Muehlebach, M. E. et al. Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity. JBMR . 9, ziae133 (2025).","journal-title":"JBMR ."},{"key":"457_CR228","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1021\/acs.jmedchem.8b00886","volume":"61","author":"CM Lacbay","year":"2018","unstructured":"Lacbay, C. M. et al. Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GGPPS) inhibitors. J. Med. Chem. 61, 6904\u20136917 (2018).","journal-title":"J. Med. Chem."},{"key":"457_CR229","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1021\/acs.jmedchem.1c01913","volume":"65","author":"HF Lee","year":"2022","unstructured":"Lee, H. F. et al. Synthesis and evaluation of structurally diverse C-2-substituted thienopyrimidine-based inhibitors of the human geranylgeranyl pyrophosphate synthase. J. Med. Chem. 65, 2471\u20132496 (2022).","journal-title":"J. Med. Chem."},{"key":"457_CR230","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.1021\/acs.jmedchem.3c01271","volume":"66","author":"R Boutin","year":"2023","unstructured":"Boutin, R. et al. Discovery and evaluation of C6-substituted pyrazolopyrimidine-based bisphosphonate inhibitors of the human geranylgeranyl pyrophosphate synthase and evaluation of their antitumor efficacy in multiple myeloma, pancreatic ductal adenocarcinoma, and colorectal cancer. J. Med. Chem. 66, 15776\u201315800 (2023).","journal-title":"J. Med. Chem."},{"key":"457_CR231","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425\u2013479 (1998).","journal-title":"Annu. Rev. Biochem."},{"key":"457_CR232","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907\u20134916 (2006).","journal-title":"Blood"},{"key":"457_CR233","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane, R. C., Bross, P. F., Farrell, A. T. & Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8, 508\u2013513 (2003).","journal-title":"Oncologist"},{"key":"457_CR234","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/2040620716648566","volume":"7","author":"B Hambley","year":"2016","unstructured":"Hambley, B., Caimi, P. F. & William, B. M. Bortezomib for the treatment of mantle cell lymphoma: an update. Ther. Adv. Hematol. 7, 196\u2013208 (2016).","journal-title":"Ther. Adv. Hematol."},{"key":"457_CR235","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487\u20132498 (2005).","journal-title":"N. Engl. J. Med."},{"key":"457_CR236","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.21310","volume":"84","author":"A Pennisi","year":"2009","unstructured":"Pennisi, A. et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am. J. Hematol. 84, 6\u201314 (2009).","journal-title":"Am. J. Hematol."},{"key":"457_CR237","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cncr.28481","volume":"120","author":"M Mohty","year":"2014","unstructured":"Mohty, M. et al. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer 120, 618\u2013623 (2014).","journal-title":"Cancer"},{"key":"457_CR238","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13287-020-02037-3","volume":"11","author":"D Zhang","year":"2020","unstructured":"Zhang, D. et al. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Res. Ther. 11, 516 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"457_CR239","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3324\/haematol.2010.031302","volume":"96","author":"M Zangari","year":"2011","unstructured":"Zangari, M. et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 96, 333\u2013336 (2011).","journal-title":"Haematologica"},{"key":"457_CR240","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari, M. et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br. J. Haematol. 131, 71\u201373 (2005).","journal-title":"Br. J. Haematol."},{"key":"457_CR241","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0609.2008.01164.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider, U. et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur. J. Haematol. 82, 31\u201338 (2009).","journal-title":"Eur. J. Haematol."},{"key":"457_CR242","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","volume":"86","author":"M Delforge","year":"2011","unstructured":"Delforge, M. et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur. J. Haematol. 86, 372\u2013384 (2011).","journal-title":"Eur. J. Haematol."},{"key":"457_CR243","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/leu.2013.267","volume":"28","author":"E Terpos","year":"2014","unstructured":"Terpos, E. et al. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia 28, 928\u2013934 (2014).","journal-title":"Leukemia"},{"key":"457_CR244","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos, E. et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br. J. Haematol. 135, 688\u2013692 (2006).","journal-title":"Br. J. Haematol."},{"key":"457_CR245","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3816\/CLM.2007.n.045","volume":"7","author":"GL Uy","year":"2007","unstructured":"Uy, G. L. et al. Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin. Lymphoma Myeloma 7, 587\u2013589 (2007).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"457_CR246","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I von Metzler","year":"2007","unstructured":"von Metzler, I. et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21, 2025\u20132034 (2007).","journal-title":"Leukemia"},{"key":"457_CR247","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","volume":"333","author":"I Zavrski","year":"2005","unstructured":"Zavrski, I. et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem. Biophys. Res. Commun. 333, 200\u2013205 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"457_CR248","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon, T. M. et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin. Cancer Res. 19, 4559\u20134563 (2013).","journal-title":"Clin. Cancer Res."},{"key":"457_CR249","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","volume":"15","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor, O. A. et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15, 7085\u20137091 (2009).","journal-title":"Clin. Cancer Res."},{"key":"457_CR250","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","volume":"18","author":"M Alsina","year":"2012","unstructured":"Alsina, M. et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin. Cancer Res. 18, 4830\u20134840 (2012).","journal-title":"Clin. Cancer Res."},{"key":"457_CR251","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","volume":"158","author":"R Vij","year":"2012","unstructured":"Vij, R. et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158, 739\u2013748 (2012).","journal-title":"Br. J. Haematol."},{"key":"457_CR252","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij, R. et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood 119, 5661\u20135670 (2012).","journal-title":"Blood"},{"key":"457_CR253","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/leu.2012.183","volume":"27","author":"MA Hurchla","year":"2013","unstructured":"Hurchla, M. A. et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27, 430\u2013440 (2013).","journal-title":"Leukemia"},{"key":"457_CR254","doi-asserted-by":"crossref","unstructured":"Terpos, E. et al. Carfilzomib improves bone metabolism in patients with advanced relapsed\/refractory multiple myeloma: results of the CarMMa study. Cancers 13, 1257 (2021).","DOI":"10.3390\/cancers13061257"},{"key":"457_CR255","doi-asserted-by":"publisher","first-page":"16918","DOI":"10.1074\/jbc.M115.663963","volume":"290","author":"Y Yang","year":"2015","unstructured":"Yang, Y., Blair, H. C., Shapiro, I. M. & Wang, B. The proteasome inhibitor carfilzomib suppresses parathyroid hormone-induced osteoclastogenesis through a RANKL-mediated signaling pathway. J. Biol. Chem. 290, 16918\u201316928 (2015).","journal-title":"J. Biol. Chem."},{"key":"457_CR256","first-page":"1826","volume":"130","author":"A Suvannasankha","year":"2017","unstructured":"Suvannasankha, A. et al. Phase 2 study of carfilzomib and bone metabolism in patients with relapsed multiple myeloma. Blood 130, 1826\u20131826 (2017).","journal-title":"Blood"},{"key":"457_CR257","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"457_CR258","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","volume":"20","author":"A Garcia-Gomez","year":"2014","unstructured":"Garcia-Gomez, A. et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin. Cancer Res. 20, 1542\u20131554 (2014).","journal-title":"Clin. Cancer Res."},{"key":"457_CR259","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jbmr.4807","volume":"38","author":"M Diaz-delCastillo","year":"2023","unstructured":"Diaz-delCastillo, M. et al. Increased bone volume by ixazomib in multiple myeloma: 3-month results from an open label phase 2 study. J. Bone Min. Res. 38, 639\u2013649 (2023).","journal-title":"J. Bone Min. Res."},{"key":"457_CR260","doi-asserted-by":"crossref","unstructured":"Harris, M. A. et al. The proteasome inhibitor ixazomib inhibits the formation and growth of pulmonary and abdominal osteosarcoma metastases in mice. Cancers 12, 1207 (2020).","DOI":"10.3390\/cancers12051207"},{"key":"457_CR261","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10637-017-0509-1","volume":"36","author":"N Gupta","year":"2018","unstructured":"Gupta, N. et al. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. Investig. New Drugs 36, 407\u2013415 (2018).","journal-title":"Investig. New Drugs"},{"key":"457_CR262","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","volume":"34","author":"JR Infante","year":"2016","unstructured":"Infante, J. R. et al. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investig. New Drugs 34, 216\u2013224 (2016).","journal-title":"Investig. New Drugs"},{"key":"457_CR263","doi-asserted-by":"publisher","first-page":"106172","DOI":"10.1016\/j.leukres.2019.106172","volume":"83","author":"P Hari","year":"2019","unstructured":"Hari, P. et al. Efficacy and safety results from a phase 1b\/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma. Leuk. Res. 83, 106172 (2019).","journal-title":"Leuk. Res."},{"key":"457_CR264","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clml.2019.05.017","volume":"19","author":"J Shah","year":"2019","unstructured":"Shah, J. et al. Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19, 570\u2013578 e1 (2019).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"457_CR265","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2007-04-084996","volume":"110","author":"KS Ahn","year":"2007","unstructured":"Ahn, K. S. et al. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 110, 2286\u20132295 (2007).","journal-title":"Blood"},{"key":"457_CR266","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan, D. et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 8, 407\u2013419 (2005).","journal-title":"Cancer Cell."},{"key":"457_CR267","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","volume":"22","author":"SJ Harrison","year":"2016","unstructured":"Harrison, S. J. et al. Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results. Clin. Cancer Res. 22, 4559\u20134566 (2016).","journal-title":"Clin. Cancer Res."},{"key":"457_CR268","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson, P. G. et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood 127, 2693\u20132700 (2016).","journal-title":"Blood"},{"key":"457_CR269","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-23-1182","volume":"29","author":"ME Stokes","year":"2023","unstructured":"Stokes, M. E. et al. PERK inhibition by HC-5404 sensitizes renal cell carcinoma tumor models to antiangiogenic tyrosine kinase inhibitors. Clin. Cancer Res. 29, 4870\u20134882 (2023).","journal-title":"Clin. Cancer Res."},{"key":"457_CR270","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/1538-7445.AM2023-1615","volume":"83","author":"C Perrera","year":"2023","unstructured":"Perrera, C. et al. Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models. Cancer Res. 83, 1615\u20131615 (2023).","journal-title":"Cancer Res."},{"key":"457_CR271","doi-asserted-by":"crossref","unstructured":"Gabrail, N. Y. et al. A phase 1\/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 39, 3080\u20133080 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.3080"},{"key":"457_CR272","doi-asserted-by":"publisher","first-page":"9480","DOI":"10.1021\/acs.jmedchem.5b01346","volume":"58","author":"HJ Zhou","year":"2015","unstructured":"Zhou, H. J. et al. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083). J. Med. Chem. 58, 9480\u20139497 (2015).","journal-title":"J. Med. Chem."},{"key":"457_CR273","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","volume":"16","author":"R Le Moigne","year":"2017","unstructured":"Le Moigne, R. et al. The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma. Mol. Cancer Ther. 16, 2375\u20132386 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"457_CR274","doi-asserted-by":"publisher","first-page":"12331","DOI":"10.18632\/oncotarget.2589","volume":"5","author":"BR Lee","year":"2014","unstructured":"Lee, B. R. et al. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget 5, 12331\u201312345 (2014).","journal-title":"Oncotarget"},{"key":"457_CR275","first-page":"2292","volume":"7","author":"J Gilbert","year":"2001","unstructured":"Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292\u20132300 (2001).","journal-title":"Clin. Cancer Res."},{"key":"457_CR276","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10637-006-9017-4","volume":"25","author":"LH Camacho","year":"2007","unstructured":"Camacho, L. H. et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Investig. New Drugs 25, 131\u2013138 (2007).","journal-title":"Investig. New Drugs"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-025-00457-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-025-00457-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-025-00457-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:38:11Z","timestamp":1757450291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-025-00457-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":276,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1038\/s41413-025-00457-6","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}